Mounjaro is one of the most effective weight loss medications available today. In clinical trials, people taking the highest dose lost an average of 20% of their body weight over about a year and a half, which translates to roughly 50 pounds for many participants. That puts it ahead of every other injectable weight loss drug tested in head-to-head studies.
How Mounjaro Works
Most weight loss injections target a single gut hormone called GLP-1. Mounjaro targets two: GLP-1 and a second hormone called GIP. Both hormones are naturally released after you eat, and they work together to slow digestion, reduce appetite, and help your body regulate blood sugar. By activating both pathways simultaneously, Mounjaro suppresses hunger more powerfully than drugs that only target one.
Interestingly, Mounjaro doesn’t just copy what these natural hormones do. It activates the GLP-1 pathway in a slightly different way than your body’s own GLP-1, which causes the receptor to stay sensitive longer instead of going numb to the signal. This may be one reason it produces stronger results than older medications in the same class.
What the Clinical Trials Show
The landmark SURMOUNT-1 trial tested Mounjaro at three doses (5 mg, 10 mg, and 15 mg) against a placebo in people with obesity or overweight who did not have diabetes. The trial ran for 72 weeks. All three doses produced significant weight loss compared to placebo, with higher doses producing greater results.
A more telling test came in the SURMOUNT-5 trial, which compared Mounjaro directly against semaglutide (the active ingredient in Wegovy and Ozempic). Participants on Mounjaro lost 20.2% of their body weight on average, compared to 13.7% for those on semaglutide. In absolute terms, that’s about 50 pounds lost with Mounjaro versus 33 pounds with semaglutide, a 47% greater reduction. Waist circumference dropped by 7.2 inches with Mounjaro compared to 5.1 inches with semaglutide.
An earlier trial in people with type 2 diabetes (SURPASS-2) showed a similar pattern. Mounjaro at its three dose levels led to 17 to 25 pounds of weight loss on average, while semaglutide at 1 mg produced about 13 pounds. A large meta-analysis covering 22 studies and over 18,000 participants confirmed that Mounjaro at 10 mg or 15 mg consistently outperformed semaglutide across the board.
How the Dosing Works
Mounjaro is a once-weekly injection you give yourself, typically in the stomach, thigh, or upper arm. You start at a low dose of 2.5 mg for the first four weeks. This starting dose isn’t meant to produce major weight loss. It’s designed to let your body adjust and minimize side effects.
After those first four weeks, the dose increases to 5 mg. From there, your doctor can raise it in 2.5 mg steps every four weeks or longer, depending on how you respond and what you can tolerate. The maximum dose is 15 mg per week. Most of the dramatic weight loss results from trials came at the 10 mg and 15 mg doses, so reaching those levels is generally the goal. The full titration schedule can take several months before you’re on your target dose, and meaningful weight loss typically builds gradually over that period.
Common Side Effects
The most frequent side effects are digestive. In clinical trials, up to 22% of people on Mounjaro experienced nausea, making it the single most common complaint. Diarrhea affected 12% to 17% of participants, and about 1 in 10 reported vomiting. These side effects tend to be worst during the first few weeks on a new dose and often improve as your body adjusts. The gradual dose increases are specifically designed to reduce their severity.
For most people, digestive symptoms are manageable and temporary. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. Some people find that certain dose levels are their ceiling because side effects become too uncomfortable to tolerate a higher dose.
Serious Risks to Know About
Mounjaro carries an FDA boxed warning about thyroid tumors. In animal studies, the drug caused thyroid C-cell tumors in rats at doses similar to those used in humans. Whether this translates to a risk in people is still unknown, but the warning is serious enough that Mounjaro is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, or persistent hoarseness while taking Mounjaro, those warrant prompt medical attention.
Acute pancreatitis is another recognized risk. Cases of severe pancreatic inflammation, including some fatal ones, have been reported in people taking GLP-1 receptor agonists including Mounjaro. Persistent, severe abdominal pain (sometimes radiating to the back) is the key symptom to watch for.
Who Can Get a Prescription
In the U.S., Mounjaro is FDA-approved for type 2 diabetes. Its sister product Zepbound contains the same active ingredient (tirzepatide) and is approved specifically for weight management. In practice, some doctors prescribe Mounjaro off-label for weight loss. To qualify for a weight management prescription, you generally need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease.
In the UK, the NHS has taken a more restrictive approach. Initial access through primary care requires a BMI of 40 or more along with at least four weight-related health conditions like high blood pressure, abnormal blood fat levels, sleep apnea, cardiovascular disease, or type 2 diabetes.
What It Costs
The retail price of Mounjaro is around $1,112 per month as of early 2026. Whether insurance covers it depends heavily on your plan, and many insurers require prior authorization, meaning your doctor has to make a case for why you need it before coverage kicks in. If you have commercial insurance, Eli Lilly offers a savings card that can bring your copay down to as little as $25 per month. Without insurance or a savings program, you’re looking at the full retail price, which puts it out of reach for many people. Prior authorization can be a frustrating process, and some plans simply don’t cover weight loss medications at all.
What to Realistically Expect
Mounjaro produces more weight loss than any other approved injectable medication for obesity, but results vary widely from person to person. The 20% average weight loss seen in trials is exactly that: an average. Some people lose considerably more, while others see more modest results. Weight loss is gradual, typically accelerating as doses increase over the first several months, with most of the effect occurring within the first 72 weeks.
The drug works best alongside dietary changes and physical activity, though the appetite suppression it provides makes those changes significantly easier for most people. One important consideration: current evidence suggests that weight tends to return if the medication is stopped, similar to what happens when people discontinue other obesity medications. For many users, Mounjaro is a long-term or indefinite treatment rather than a short course.